InsidersTradesSigma
Follow the InspireMD, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, InspireMD, Inc. has published 21 reports. Market capitalisation: €32.9m. The latest transaction was disclosed on 15 May 2026 (Acquisition). Among the most active insiders: Stuka Paul. Every trade is free.
21
Insider Decl.
n/a
Thresholds
€519,865
11 ops.
Buy Volume
n/a
n/a
Sell Volume
43Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 28,332 of 29,063 companies
11.2
score / 100
Value1
Quality21
FCF yld-92%
Earn yld-123%
EV/EBITDA·
ROE-203%
Gross mgn30%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 15 May 2026
Declarations21 total
10,000 shares@ US$1.15750.020% mcap1.6% of flowCommon StockSEC:0001493152-26-023727:0
Canonical exit: 11 Aug 2026 (T+90)
65,626 shares@ US$1.160.13% mcap10.5% of flowCommon StockSEC:0001493152-26-022763:0
Canonical exit: 6 Aug 2026 (T+90)
65,626 shares@ US$1.160.13% mcap10.5% of flowCommon StockSEC:0001493152-26-022564:0
Canonical exit: 6 Aug 2026 (T+90)
72,978 shares0Common StockSEC:0001493152-22-000554:0
16,393 shares@ US$3.07670.090% mcap10.5% of flowCommon StockSEC:0001493152-21-032757:0
Canonical exit: 28 Mar 2022 (T+90)
12,037 shares@ US$3.51320.076% mcap6.0% of flowCommon StockSEC:0001493152-21-030337:0
Canonical exit: 1 Mar 2022 (T+90)
3,177 shares@ US$3.550.020% mcap1.6% of flowCommon StockSEC:0001493152-21-030119:0
Canonical exit: 27 Feb 2022 (T+90)
1,200 shares@ US$3.550.0077% mcap0.6% of flowCommon StockSEC:0001493152-21-030004:0
Canonical exit: 24 Feb 2022 (T+90)
18,328 shares@ US$3.550.12% mcap9.4% of flowCommon StockSEC:0001493152-21-029925:0
Canonical exit: 22 Feb 2022 (T+90)
19,188 shares@ US$3.53730.12% mcap9.7% of flowCommon StockSEC:0001493152-21-029722:0
Canonical exit: 20 Feb 2022 (T+90)
25,640 shares@ US$3.8560.18% mcap20.7% of flowCommon StockSEC:0001493152-21-029222:0
Canonical exit: 15 Feb 2022 (T+90)
17,248 shares0Common StockSEC:0001493152-21-028170:0
72,978 shares0Common StockSEC:0001493152-21-028168:0
146,567 shares0Restricted Stock UnitsSEC:0001493152-21-025454:0
26,079 shares0Common StockSEC:0001493152-21-025455:0
17,248 shares0Common StockSEC:0001493152-21-025451:0
17,248 shares0Common StockSEC:0001493152-21-025452:0
17,248 shares0Common StockSEC:0001493152-21-025453:0
17,248 shares0Common StockSEC:0001493152-21-025456:0
22,249 shares@ US$4.1910.16% mcap18.8% of flowCommon StockSEC:0001493152-21-021349:0
Canonical exit: 23 Nov 2021 (T+90)
10,536 shares0Common StockSEC:0001493152-21-011070:0
21 of 21 declarations
关于 InspireMD, Inc.
InspireMD, Inc. (纳斯达克代码: NSPR) 是一家总部位于美国的医疗器械公司，致力于通过颈动脉支架解决方案预防中风。公司总部设在佛罗里达州迈阿密，在以色列特拉维夫拥有重要的运营业务。公司成立于 2005 年，在纳斯达克资本市场交易。其商业模式以开发、商业化和扩展专有的栓塞保护平台为核心，旨在改善血管介入治疗的临床结果。([investors.inspiremd.com](https://investors.inspiremd.com/ir-resources/investor-faqs?utm_source=openai)) 公司的核心技术是 MicroNet™，这是一种专有网状结构，旨在减少颈动脉治疗过程中的斑块脱垂和栓塞碎片。InspireMD 的旗舰产品是 CGuard Prime，这是一种用于预防中风的颈动脉支架系统，管理层还强调该平台在颈动脉疾病之外具有更广泛的潜在应用。历史上，InspireMD 已在国际市场商业化 CGuard 和 MGuard Prime，积累了美国以外的临床经验和监管熟悉度。([inspiremd.com](https://inspiremd.com/about/?utm_source=openai)) 从竞争角度来看，InspireMD 在一个高度专业化的利基市场中运营，与规模更大、拥有更多制造、商业和监管资源的多国医疗器械公司竞争。因此，公司的差异化基于技术、临床证据以及在颈动脉栓塞保护方面的专注定位。如果医生采纳和报销支持规模扩大，这种专业化可能具有吸引力，但它也使股票面临执行、资金和商业化风险。([inspiremd.com](https://inspiremd.com/news/inspiremd-announces-establishment-of-global-headquarters-in-miami-florida-to-support-anticipated-u-s-launch-and-commercialization-of-the-cguard-prime-carotid-stent-system/?utm_source=openai)) 最近最重要的进展是 2025 年 6 月 24 日宣布的 FDA 批准 CGuard Prime 颈动脉支架系统，这是一个支持美国商业化的重要里程碑。InspireMD 已于 2024 年 10 月在迈阿密设立了全球总部，为预期的美国上市做准备。公司 2024 年和 2025 年的财务更新也表明对美国商业基础设施的投资不断增加，这标志着从主要国际商业足迹向更完善的国内业务的过渡。([investors.inspiremd.com](https://investors.inspiremd.com/news-releases/news-release-details/inspiremd-announces-fda-approval-cguardr-prime-carotid-stent?utm_source=openai)) 对于法语投资者而言，InspireMD 是一家在美国上市的医疗保健公司，具有重要的监管和商业选择权，但其仍依赖于成功的美国上市执行、地域扩张以及将临床数据转化为可持续的收入增长。([investors.inspiremd.com](https://investors.inspiremd.com/ir-resources/investor-faqs?utm_source=openai))
